Orlando Magic · — · #—
—
| Period | GP | MIN | PTS | REB | AST | PRA | STL | BLK | TOV | 2PM | 2PA | 2P% | 3PM | 3PA | 3P% | FTM | FTA | FT% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Last 3 | 3 | 27.8 | 15.3 | 2.3 | 3.7 | 21.3 | 1.0 | 0.3 | 2.7 | 0.7 | 1.7 |
| 40.0% |
| 4.7 |
| 9.7 |
| 48.3% |
| 0.0 |
| 0.0 |
| 0.0% |
| Last 5 | 5 | 30.2 | 13.8 | 3.4 | 6.2 | 23.4 | 1.4 | 0.4 | 2.0 | 1.0 | 3.6 | 27.8% | 3.8 | 8.8 | 43.2% | 0.4 | 0.4 | 100.0% |
| Last 10 | 10 | 30.6 | 13.6 | 4.2 | 6.5 | 24.3 | 1.8 | 0.5 | 3.2 | 2.1 | 4.5 | 46.7% | 2.8 | 7.1 | 39.4% | 1.0 | 1.0 | 100.0% |
| Last 20 | 20 | 30.4 | 14.3 | 3.9 | 5.7 | 23.9 | 1.8 | 0.5 | 2.9 | 2.7 | 4.9 | 54.5% | 2.5 | 7.0 | 36.4% | 1.2 | 1.4 | 89.3% |
| Season | 57 | 27.6 | 13.8 | 3.9 | 5.5 | 23.1 | 1.8 | 0.7 | 2.7 | 2.8 | 5.1 | 55.4% | 2.1 | 6.3 | 33.9% | 1.8 | 2.1 | 85.5% |
low rim finishing off the ball, low contested shots per minute, low offensive rebounding, high on-ball creation
2025-26 season · fitted over 2022-23–2025-26
Style profile over 446 qualified players (8+ games, 10+ min/game). 100% is an identical profile; 50% is unrelated.
| Date | Matchup | W/L | MIN | PTS | REB | AST | STL | BLK | TOV | FGM | FGA | FG% | 3PM | 3PA | 3P% | FTM | FTA | FT% | +/- |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-12 | ORL @ BOS | L | 38.0 | 23 | 6 | 3 | 1 | 1 | 4 | 8 | 17 | 47.1% | 7 | 15 | 46.7% | 0 | 0 | 0.0% | 6.0 |
| 2026-04-10 | ORL @ CHI | W | 20.1 | 12 | 1 | 4 | 0 | 0 | 2 | 4 | 11 | 36.4% | 4 | 9 | 44.4% | 0 | 0 | 0.0% | 13.0 |
| 2026-04-08 | ORL vs. MIN | W | 25.3 | 11 | 0 | 4 | 2 | 0 | 2 | 4 | 6 | 66.7% | 3 | 5 | 60.0% | 0 | 0 | 0.0% | 13.0 |
| 2026-04-06 | ORL vs. DET | W | 33.9 | 12 | 6 | 12 | 3 | 1 | 1 | 4 | 9 | 44.4% | 2 | 3 | 66.7% | 2 | 2 | 100.0% | 30.0 |
| 2026-04-05 | ORL @ NOP | W | 33.6 | 11 | 4 | 8 | 1 | 0 | 1 | 4 | 19 | 21.1% | 3 | 12 | 25.0% | 0 | 0 | 0.0% | -1.0 |
| 2026-04-03 | ORL @ DAL | W | 31.2 | 19 | 4 | 9 | 3 | 0 | 3 | 8 | 12 | 66.7% | 3 | 6 | 50.0% | 0 | 0 | 0.0% | 0.0 |
| 2026-04-01 | ORL vs. ATL | L | 26.0 | 7 | 5 | 9 | 3 | 1 | 6 | 3 | 12 | 25.0% | 0 | 5 | 0.0% | 1 | 1 | 100.0% | -13.0 |
| 2026-03-31 | ORL vs. PHX | W | 37.7 | 20 | 8 | 7 | 4 | 0 | 6 | 6 | 11 | 54.5% | 2 | 5 | 40.0% | 6 | 6 | 100.0% | 15.0 |
| 2026-03-29 | ORL @ TOR | L | 25.9 | 13 | 4 | 5 | 1 | 1 | 5 | 5 | 11 | 45.5% | 2 | 6 | 33.3% | 1 | 1 | 100.0% | -16.0 |
| 2026-03-26 | ORL vs. SAC | W | 34.0 | 8 | 4 | 4 | 0 | 1 | 2 | 3 | 8 | 37.5% | 2 | 5 | 40.0% | 0 | 0 | 0.0% | -2.0 |
| 2026-03-21 | ORL vs. LAL | L | 34.3 | 14 | 3 | 6 | 1 | 0 | 3 | 5 | 9 | 55.6% | 2 | 6 | 33.3% | 2 | 2 | 100.0% | -20.0 |
| 2026-03-19 | ORL @ CHA | L | 21.9 | 9 | 0 | 1 | 2 | 1 | 2 | 4 | 12 | 33.3% | 1 | 5 | 20.0% | 0 | 0 | 0.0% | -15.0 |
| 2026-03-17 | ORL vs. OKC | L | 32.6 | 14 | 7 | 6 | 1 | 1 | 2 | 5 | 12 | 41.7% | 4 | 9 | 44.4% | 0 | 0 | 0.0% | -5.0 |
| 2026-03-16 | ORL @ ATL | L | 28.4 | 8 | 6 | 5 | 1 | 1 | 3 | 4 | 11 | 36.4% | 0 | 5 | 0.0% | 0 | 0 | 0.0% | -10.0 |
| 2026-03-14 | ORL @ MIA | W | 34.2 | 14 | 5 | 6 | 1 | 0 | 3 | 6 | 17 | 35.3% | 2 | 9 | 22.2% | 0 | 2 | 0.0% | -1.0 |
| 2026-03-12 | ORL vs. WAS | W | 34.1 | 28 | 4 | 8 | 2 | 0 | 3 | 10 | 17 | 58.8% | 3 | 8 | 37.5% | 5 | 6 | 83.3% | 6.0 |
| 2026-03-11 | ORL vs. CLE | W | 31.8 | 12 | 2 | 4 | 3 | 0 | 2 | 4 | 9 | 44.4% | 1 | 5 | 20.0% | 3 | 3 | 100.0% | 3.0 |
| 2026-03-08 | ORL @ MIL | W | 23.7 | 20 | 3 | 2 | 2 | 0 | 5 | 7 | 9 | 77.8% | 3 | 3 | 100.0% | 3 | 3 | 100.0% | 23.0 |
| 2026-03-07 | ORL @ MIN | W | 29.3 | 14 | 4 | 4 | 2 | 1 | 1 | 5 | 13 | 38.5% | 3 | 8 | 37.5% | 1 | 1 | 100.0% | 13.0 |
| 2026-03-05 | ORL vs. DAL | W | 31.5 | 17 | 2 | 7 | 2 | 1 | 2 | 6 | 14 | 42.9% | 4 | 11 | 36.4% | 1 | 1 | 100.0% | 9.0 |
| 2026-03-03 | ORL vs. WAS | W | 26.5 | 10 | 3 | 9 | 2 | 2 | 2 | 5 | 9 | 55.6% | 0 | 2 | 0.0% | 0 | 0 | 0.0% | 10.0 |
| 2026-03-01 | ORL vs. DET | L | 26.5 | 14 | 3 | 4 | 0 | 1 | 2 | 4 | 17 | 23.5% | 4 | 13 | 30.8% | 2 | 2 | 100.0% | 2.0 |
| 2026-02-26 | ORL vs. HOU | L | 13.3 | 3 | 1 | 0 | 2 | 1 | 4 | 1 | 6 | 16.7% | 0 | 1 | 0.0% | 1 | 2 | 50.0% | -11.0 |
| 2026-02-19 | ORL @ SAC | W | 19.8 | 9 | 3 | 3 | 0 | 1 | 3 | 3 | 8 | 37.5% | 3 | 7 | 42.9% | 0 | 0 | 0.0% | -7.0 |
| 2026-02-11 | ORL vs. MIL | L | 34.9 | 16 | 1 | 10 | 4 | 3 | 1 | 5 | 14 | 35.7% | 4 | 11 | 36.4% | 2 | 2 | 100.0% | -2.0 |
| 2026-02-09 | ORL vs. MIL | W | 26.8 | 7 | 3 | 10 | 5 | 1 | 2 | 3 | 7 | 42.9% | 1 | 3 | 33.3% | 0 | 0 | 0.0% | 9.0 |
| 2026-02-07 | ORL vs. UTA | W | 34.4 | 12 | 7 | 6 | 4 | 2 | 2 | 4 | 11 | 36.4% | 2 | 7 | 28.6% | 2 | 4 | 50.0% | 13.0 |
| 2026-02-05 | ORL vs. BKN | W | 29.1 | 15 | 11 | 11 | 3 | 4 | 3 | 6 | 9 | 66.7% | 3 | 5 | 60.0% | 0 | 0 | 0.0% | 24.0 |
| 2026-02-03 | ORL @ OKC | L | 24.6 | 20 | 3 | 6 | 1 | 0 | 3 | 7 | 11 | 63.6% | 4 | 8 | 50.0% | 2 | 2 | 100.0% | -4.0 |
| 2026-02-01 | ORL @ SAS | L | 32.5 | 5 | 6 | 6 | 1 | 1 | 4 | 2 | 13 | 15.4% | 1 | 6 | 16.7% | 0 | 0 | 0.0% | -15.0 |
| 2026-01-30 | ORL vs. TOR | W | 33.2 | 14 | 6 | 10 | 3 | 0 | 1 | 5 | 14 | 35.7% | 3 | 8 | 37.5% | 1 | 1 | 100.0% | 13.0 |
| 2026-01-28 | ORL @ MIA | W | 29.2 | 16 | 5 | 4 | 0 | 1 | 2 | 6 | 15 | 40.0% | 1 | 7 | 14.3% | 3 | 4 | 75.0% | -3.0 |
| 2026-01-26 | ORL @ CLE | L | 27.3 | 4 | 5 | 6 | 2 | 1 | 3 | 2 | 13 | 15.4% | 0 | 5 | 0.0% | 0 | 0 | 0.0% | -6.0 |
| 2026-01-24 | ORL vs. CLE | L | 24.4 | 9 | 1 | 6 | 0 | 0 | 1 | 3 | 6 | 50.0% | 1 | 4 | 25.0% | 2 | 2 | 100.0% | -17.0 |
| 2026-01-02 | ORL @ CHI | L | 20.1 | 11 | 3 | 4 | 1 | 0 | 1 | 4 | 6 | 66.7% | 1 | 1 | 100.0% | 2 | 2 | 100.0% | 15.0 |
| 2025-12-31 | ORL @ IND | W | 25.4 | 11 | 3 | 3 | 3 | 0 | 3 | 4 | 11 | 36.4% | 1 | 4 | 25.0% | 2 | 3 | 66.7% | 2.0 |
| 2025-12-13 | ORL @ NYK | L | 29.5 | 26 | 2 | 7 | 0 | 0 | 2 | 10 | 16 | 62.5% | 2 | 8 | 25.0% | 4 | 6 | 66.7% | 8.0 |
| 2025-12-09 | ORL vs. MIA | W | 31.0 | 20 | 3 | 4 | 2 | 0 | 4 | 7 | 13 | 53.8% | 3 | 8 | 37.5% | 3 | 4 | 75.0% | 4.0 |
| 2025-12-07 | ORL @ NYK | L | 31.8 | 17 | 3 | 4 | 2 | 1 | 2 | 6 | 16 | 37.5% | 1 | 6 | 16.7% | 4 | 5 | 80.0% | 2.0 |
| 2025-12-05 | ORL vs. MIA | W | 28.4 | 22 | 3 | 5 | 1 | 1 | 1 | 9 | 19 | 47.4% | 4 | 7 | 57.1% | 0 | 0 | 0.0% | 0.0 |
| 2025-12-03 | ORL vs. SAS | L | 27.4 | 24 | 4 | 4 | 3 | 0 | 1 | 10 | 20 | 50.0% | 3 | 8 | 37.5% | 1 | 2 | 50.0% | -1.0 |
| 2025-12-01 | ORL vs. CHI | W | 30.0 | 10 | 4 | 4 | 5 | 1 | 4 | 3 | 13 | 23.1% | 2 | 10 | 20.0% | 2 | 2 | 100.0% | -9.0 |
| 2025-11-28 | ORL @ DET | W | 33.9 | 14 | 4 | 1 | 4 | 1 | 2 | 4 | 17 | 23.5% | 2 | 11 | 18.2% | 4 | 4 | 100.0% | -20.0 |
| 2025-11-25 | ORL @ PHI | W | 15.7 | 4 | 5 | 11 | 2 | 2 | 1 | 2 | 7 | 28.6% | 0 | 3 | 0.0% | 0 | 0 | 0.0% | 12.0 |
| 2025-11-22 | ORL vs. NYK | W | 31.8 | 26 | 3 | 1 | 0 | 0 | 4 | 8 | 15 | 53.3% | 2 | 6 | 33.3% | 8 | 9 | 88.9% | 9.0 |
| 2025-11-20 | ORL vs. LAC | W | 26.3 | 23 | 3 | 7 | 2 | 2 | 3 | 8 | 15 | 53.3% | 5 | 9 | 55.6% | 2 | 2 | 100.0% | 12.0 |
| 2025-11-18 | ORL vs. GSW | W | 31.9 | 13 | 5 | 8 | 2 | 1 | 3 | 4 | 11 | 36.4% | 0 | 7 | 0.0% | 5 | 5 | 100.0% | 8.0 |
| 2025-11-14 | ORL vs. BKN | W | 28.2 | 14 | 7 | 6 | 0 | 1 | 5 | 5 | 11 | 45.5% | 2 | 7 | 28.6% | 2 | 2 | 100.0% | 11.0 |
| 2025-11-12 | ORL @ NYK | W | 26.4 | 14 | 2 | 3 | 1 | 1 | 2 | 4 | 10 | 40.0% | 1 | 5 | 20.0% | 5 | 6 | 83.3% | 10.0 |
| 2025-11-09 | ORL vs. BOS | L | 28.6 | 20 | 8 | 4 | 3 | 0 | 3 | 6 | 8 | 75.0% | 2 | 4 | 50.0% | 6 | 7 | 85.7% | 21.0 |
| 2025-11-07 | ORL vs. BOS | W | 20.8 | 14 | 3 | 5 | 0 | 0 | 3 | 5 | 8 | 62.5% | 4 | 6 | 66.7% | 0 | 0 | 0.0% | 7.0 |
| 2025-11-04 | ORL @ ATL | L | 20.4 | 12 | 2 | 4 | 3 | 0 | 2 | 4 | 8 | 50.0% | 2 | 3 | 66.7% | 2 | 2 | 100.0% | -6.0 |
| 2025-11-01 | ORL @ WAS | W | 19.3 | 6 | 2 | 5 | 5 | 0 | 3 | 3 | 10 | 30.0% | 0 | 7 | 0.0% | 0 | 0 | 0.0% | 22.0 |
| 2025-10-29 | ORL @ DET | L | 20.7 | 8 | 2 | 5 | 2 | 1 | 2 | 1 | 4 | 25.0% | 1 | 3 | 33.3% | 5 | 5 | 100.0% | 10.0 |
| 2025-10-27 | ORL @ PHI | L | 20.5 | 12 | 6 | 6 | 0 | 0 | 4 | 4 | 7 | 57.1% | 1 | 3 | 33.3% | 3 | 4 | 75.0% | -9.0 |
| 2025-10-24 | ORL vs. ATL | L | 19.1 | 11 | 3 | 4 | 0 | 0 | 4 | 4 | 5 | 80.0% | 3 | 4 | 75.0% | 0 | 0 | 0.0% | 4.0 |
| 2025-10-22 | ORL vs. MIA | W | 16.5 | 14 | 4 | 2 | 2 | 0 | 2 | 6 | 7 | 85.7% | 2 | 3 | 66.7% | 0 | 0 | 0.0% | 15.0 |